EAU 2017: A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)

London, England (UroToday.com) Digital rectal examination (DRE) has been a standard part of the urologists’ exam for many generations, often cited to be a key component of the screening for prostate cancer.

EAU 2017: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study

London, England (UroToday.com) There is significant uncertainty on the appropriate timing for adjuvant or salvage radiation therapy (ART, SRT) after radical prostatectomy (RP). The Decipher test (GenomeDx Biosciences Inc., San Diego) measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways across the genome that are associated with aggressive prostate cancer.

EAU 2017: Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers

London, England (UroToday.com) Current tissue based prognostic biomarker assays claim that genetic assessment of a single focus is sufficient to predict disease behaviour. The investigators of this study analyzed and compared the genetic profiles of multifocal prostate cancer patients with concordant lymph node metastasis (LNM) to determine if expression based prognostic tests are robust to multi-focality.

EAU 2017: Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death

London, England (UroToday.com) Increased prostate cancer risk is associated with BRCA1/2 and ATM germline mutations. This study aimed to directly assess whether these specific germline mutations distinguish lethal from indolent prostate cancer and whether they confer any effect on age at death.

EAU 2017: Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201

London, England (UroToday.com) The androgen receptor (AR) plays a key role in the treatment of prostate cancer and its lethal castration-resistant form. Treatment with first line treatment approved AR inhibitors eventually results in the inevitable treatment resistance.

EAU 2017: Systems pharmacology and quantitative proteomics for developing targeted triple therapy

London, England (UroToday.com) Pathway specific inhibitors which block signaling pathways activated for solid tumor growth are being used to reduce tumor load. Despite this approach being successful, it is still challenging to predict which drug combinations will be the most potent.

EAU 2017: State of the Art Lecture: Enhanced recovery after surgery (ERAS) for bladder cancer: non-surgical options to improve outcomes of cystectomy

London, England (UroToday.com) In this session, Professor Catto discussed non-surgical options for improving outcomes of cystectomy. Radical cystectomy is a morbid operation with 64% of patients having any complication, 13% having a major complication, and 20% being readmitted after surgery.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.